Influenza News and Research

Latest Influenza News and Research

Emerging H7N9 virus has potential to cause a pandemic

A new study has found that a novel avian-origin H7N9 influenza A virus, which has recently emerged in humans, attaches moderately or abundantly to the epithelium of both the upper and lower respiratory tracts.

10 Sep 2013

Scientists identify RNA regulator that plays critical role in proper functioning of hESCs

Scientists at A*STAR's Genome Institute of Singapore, in collaboration with their counterparts from Canada, Hong Kong and US, have discovered a protein mediator SON plays a critical role in the health and proper functioning of human embryonic stem cells. This finding was reported on 8th September 2013 in the advanced online issue of the prestigious science journal Nature Cell Biology.

10 Sep 2013

New technology to diagnose influenza quickly

A new technology is showing promise as the basis for a much-needed home test to diagnose influenza quickly, before the window for taking antiviral drugs slams shut and sick people spread the virus to others, scientists reported here today. In a presentation at the 246th National Meeting & Exposition of the American Chemical Society (ACS), they described how it also could determine the specific strain of flu virus and help select the most effective drug for treatment.

10 Sep 2013

Avanir Pharmaceuticals, Wockhardt settle patent litigation related to NUEDEXTA capsules

Avanir Pharmaceuticals, Inc. today announced that it has entered into a settlement agreement with Wockhardt USA, LLC and Wockhardt Ltd. (collectively, "Wockhardt") to resolve pending patent litigation in response to Wockhardt's abbreviated new drug application (ANDA) seeking approval to market generic versions of Avanir's NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules.

7 Sep 2013

PaxVax commences phase 3 clinical trial for single-dose oral cholera vaccine candidate

PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced that it has commenced its Phase 3 clinical trial program for its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR). Approximately 3,000 participants will be enrolled in this pivotal program, which is comprised of cholera challenge, safety, and immunogenicity studies.

7 Sep 2013

Safety and health checklist to help kids avoid emergency room

With the school year underway, Children's Hospital Los Angeles experts have developed a safety and health checklist to help kids avoid the emergency room and develop productive extracurricular and learning activities to enhance the classroom experience. What do parents need to consider? Many symptoms of childhood conditions are often discovered in the classroom.

7 Sep 2013

Social media and online communities can improve health behaviors among men at risk of HIV

A UCLA study published Sept. 3 in the peer-reviewed journal Annals of Internal Medicine demonstrates that an approach that combines behavioral science with social media and online communities can lead to improved health behaviors among men at risk of HIV infection.

7 Sep 2013

New influenza vaccine delivered via microneedle avoids pain and side effects

Scientists have developed an influenza vaccine delivered via microneedle patch that provided 100 percent protection against a lethal influenza virus in mice more than one year after vaccination. They report their findings in the September 2013 issue of the journal Clinical and Vaccine Immunology.

5 Sep 2013

Avanir Pharmaceuticals enters into patent settlement agreement with Actavis

Avanir Pharmaceuticals, Inc. today announced that it has entered into a settlement agreement with Actavis South Atlantic LLC and Actavis, Inc. (collectively, "Actavis") to resolve pending patent litigation in response to Actavis' abbreviated new drug application seeking approval to market generic versions of Avanir's NUEDEXTA (dextromethorphan hydrobromide/quinidine sulfate) capsules.

4 Sep 2013

Imaxio's pro-immunogenic technology used in tuberculosis vaccine phase I clinical study

Imaxio, a biopharmaceutical company specializing in vaccines and genomics, announces today that IMX313, its proprietary pro-immunogenic technology, has been administered for the first time in humans in a tuberculosis vaccine phase I clinical study. The trial is being conducted by the Jenner Institute at Oxford University, England.

3 Sep 2013

Scientists estimate minimum of 320,000 viruses in mammals

Scientists estimate that there is a minimum of 320,000 viruses in mammals awaiting discovery. Collecting evidence of these viruses, or even a majority of them, they say, could provide information critical to early detection and mitigation of disease outbreaks in humans.

3 Sep 2013

Scientists determine new strategy to estimate total viral diversity in mammals

EcoHealth Alliance, a nonprofit organization that focuses on local conservation and global health issues, and the Center for Infection and Immunity (CII) at Columbia University's Mailman School of Public Health announced a new strategy to identify the total number of wildlife viruses that could potentially cause emerging disease outbreaks that threaten both public and wildlife health.

3 Sep 2013

New mothers and obese people have higher risk of severe outcomes from influenza

Although up to 500,000 people world-wide die of severe influenza each year, there has been no clear evidence about who is susceptible for influenza complications and it may not be who people think, says a study from McMaster University.

28 Aug 2013

Sanofi Pasteur reports clinical benefit of Fluzone High-Dose vaccine in preventing influenza

Sanofi Pasteur, the vaccines division of Sanofi, today announced topline results of a large-scale, multi-center efficacy trial in people 65 years of age and older showing a superior clinical benefit of Fluzone High-Dose (Influenza Virus Vaccine) relative to the standard dose of Fluzone vaccine in preventing influenza.

26 Aug 2013

Best way to protect infants from influenza is to vaccinate rest of the family

A University of Sydney study has found the best way to protect children under six months of age from influenza, the most vulnerable of the population to the condition, is to vaccinate the rest of the family.

23 Aug 2013

Novartis starts shipment of 2013-2014 seasonal influenza vaccines to US customers

Novartis announced today that it has begun shipment of its seasonal influenza vaccines to customers in the US market for the 2013-2014 season. Novartis plans to ship a minimum of 30 million doses of its influenza vaccines to the US market, including Fluvirin (Influenza Virus Vaccine), approved for use in people 4 years of age and older, and Flucelvax (Influenza Virus Vaccine), approved for use in adults 18 years of age and older.

22 Aug 2013

Kentucky researcher uses advanced biomedical technology to study HMPV

You may not know the human metapneumovirus by name, but chances are that you have met somewhere before.

22 Aug 2013

Influenza researchers use genetic sequencing to trace source and evolution of avian H7N9 virus

An international team of influenza researchers in China, the United Kingdom and the United States has used genetic sequencing to trace the source and evolution of the avian H7N9 influenza virus that emerged in humans in China earlier this year. The study, published today in Nature, was supported by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, and other organizations.

22 Aug 2013

HIV prevention program at UCLA may reduce unprotected sex among bisexual black men

A culturally tailored HIV prevention program developed and tested by investigators at UCLA and the Charles R. Drew University of Medicine and Science has been shown to significantly reduce unprotected sex among bisexual black men.

22 Aug 2013

Second GSK intramuscular quadrivalent influenza vaccine approved by the FDA

GlaxoSmithKline plc [LSE/NYSE: GSK] announced that the U.S. Food and Drug Administration (FDA) has approved FLULAVAL® QUADRIVALENT (Influenza Virus Vaccine) for the active immunization of persons three years of age and older to help prevent disease caused by seasonal influenza (flu) virus subtypes A and B contained in the vaccine.

19 Aug 2013

Influenza News and Research

Latest Influenza News and Research

Emerging H7N9 virus has potential to cause a pandemic

Scientists identify RNA regulator that plays critical role in proper functioning of hESCs

New technology to diagnose influenza quickly

Avanir Pharmaceuticals, Wockhardt settle patent litigation related to NUEDEXTA capsules

PaxVax commences phase 3 clinical trial for single-dose oral cholera vaccine candidate

Safety and health checklist to help kids avoid emergency room

Social media and online communities can improve health behaviors among men at risk of HIV

New influenza vaccine delivered via microneedle avoids pain and side effects

Avanir Pharmaceuticals enters into patent settlement agreement with Actavis

Imaxio's pro-immunogenic technology used in tuberculosis vaccine phase I clinical study

Scientists estimate minimum of 320,000 viruses in mammals

Scientists determine new strategy to estimate total viral diversity in mammals

New mothers and obese people have higher risk of severe outcomes from influenza

Sanofi Pasteur reports clinical benefit of Fluzone High-Dose vaccine in preventing influenza

Best way to protect infants from influenza is to vaccinate rest of the family

Novartis starts shipment of 2013-2014 seasonal influenza vaccines to US customers

Kentucky researcher uses advanced biomedical technology to study HMPV

Influenza researchers use genetic sequencing to trace source and evolution of avian H7N9 virus

HIV prevention program at UCLA may reduce unprotected sex among bisexual black men

Second GSK intramuscular quadrivalent influenza vaccine approved by the FDA

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Influenza News and Research

Latest Influenza News and Research

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in